SCH 56592与氟康唑和伊曲康唑对念珠菌属的活性比较
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
作者信息
Law D, Moore C B, Denning D W
机构信息
Department of Microbiology, Hope Hospital, Salford, United Kingdom.
出版信息
Antimicrob Agents Chemother. 1997 Oct;41(10):2310-1. doi: 10.1128/AAC.41.10.2310.
Abstract
The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.
摘要
将一种新型唑类药物先灵葆雅56592的体外活性与氟康唑和伊曲康唑针对包括10个不同种的103株念珠菌的活性进行了比较。先灵葆雅56592比伊曲康唑和氟康唑活性更强，并且对许多耐氟康唑的菌株都有活性。
相似文献
1
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
Antimicrob Agents Chemother. 1997 Oct;41(10):2310-1. doi: 10.1128/AAC.41.10.2310.
2
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
J Antimicrob Chemother. 1999 Aug;44(2):283-6. doi: 10.1093/jac/44.2.283.
3
Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):432-5. doi: 10.1007/s100960050313.
4
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.
Antimicrob Agents Chemother. 1999 Sep;43(9):2236-9. doi: 10.1128/AAC.43.9.2236.
5
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
J Antimicrob Chemother. 1998 Aug;42(2):253-6. doi: 10.1093/jac/42.2.253.
6
In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
J Mycol Med. 2018 Jun;28(2):310-313. doi: 10.1016/j.mycmed.2018.03.005.
7
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
Antimicrob Agents Chemother. 1997 Feb;41(2):233-5. doi: 10.1128/AAC.41.2.233.
8
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Antimicrob Agents Chemother. 2001 Oct;45(10):2862-4. doi: 10.1128/AAC.45.10.2862-2864.2001.
9
In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.
Mycoses. 2006 May;49(3):220-5. doi: 10.1111/j.1439-0507.2006.01226.x.
10
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Antimicrob Agents Chemother. 2003 Mar;47(3):1068-71. doi: 10.1128/AAC.47.3.1068-1071.2003.
引用本文的文献
1
Surfactin and Capric Acid Affect the Posaconazole Susceptibility of Strains with Altered Sterols and Sphingolipids Biosynthesis.
Int J Mol Sci. 2023 Dec 15;24(24):17499. doi: 10.3390/ijms242417499.
2
Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi.
PLoS One. 2016 Jul 20;11(7):e0158724. doi: 10.1371/journal.pone.0158724. eCollection 2016.
3
Advances in synthetic approach to and antifungal activity of triazoles.
Beilstein J Org Chem. 2011;7:668-77. doi: 10.3762/bjoc.7.79. Epub 2011 May 25.
4
In search of the holy grail of antifungal therapy.
Trans Am Clin Climatol Assoc. 2008;119:197-215; discussion 215-6.
5
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
6
Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.
Pharm World Sci. 2005 Feb;27(1):31-4. doi: 10.1007/s11096-004-1735-0.
7
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Antimicrob Agents Chemother. 2001 Mar;45(3):857-69. doi: 10.1128/AAC.45.3.857-869.2001.
8
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.
Antimicrob Agents Chemother. 2000 Aug;44(8):2017-22. doi: 10.1128/AAC.44.8.2017-2022.2000.
9
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.
Antimicrob Agents Chemother. 2000 Jan;44(1):226-9. doi: 10.1128/AAC.44.1.226-229.2000.
10
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Antimicrob Agents Chemother. 2000 Jan;44(1):150-5. doi: 10.1128/AAC.44.1.150-155.2000.
本文引用的文献
1
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
Antimicrob Agents Chemother. 1997 Feb;41(2):233-5. doi: 10.1128/AAC.41.2.233.
2
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
Antimicrob Agents Chemother. 1997 Jan;41(1):180-3. doi: 10.1128/AAC.41.1.180.
3
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3. doi: 10.1128/AAC.40.8.1910.
4
Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species.
J Antimicrob Chemother. 1995 Nov;36(5):787-93. doi: 10.1093/jac/36.5.787.
5
Improved medium for fluconazole susceptibility testing of Candida albicans.
Antimicrob Agents Chemother. 1994 Jan;38(1):45-8. doi: 10.1128/AAC.38.1.45.
6
Fluconazole-resistant candidosis in an HIV cohort.
AIDS. 1994 Jun;8(6):787-92. doi: 10.1097/00002030-199406000-00010.
7
Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
J Antimicrob Chemother. 1995 Jan;35(1):103-14. doi: 10.1093/jac/35.1.103.
8
High prevalence of antifungal resistance in Candida spp. from patients with AIDS.
J Antimicrob Chemother. 1994 Nov;34(5):659-68. doi: 10.1093/jac/34.5.659.
9
Can we prevent azole resistance in fungi?
Lancet. 1995 Aug 19;346(8973):454-5. doi: 10.1016/s0140-6736(95)91314-9.
10
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.
Antimicrob Agents Chemother. 1995 Jul;39(7):1512-6. doi: 10.1128/AAC.39.7.1512.
Zotero 插件